Expanded Access of Cabozantinib in Medullary Thyroid Cancer
NCT01683110 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2013-01-16
Summary
The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.
Conditions
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
NCT03430843 ·Status: COMPLETED ·Phase: PHASE3
-
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
NCT06079723 ·Status: NOT_YET_RECRUITING
-
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
NCT03783442 ·Status: COMPLETED ·Phase: PHASE3
-
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
NCT06991738 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
NCT00153881 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
NCT04974047 ·Status: COMPLETED ·Phase: PHASE2
-
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT05007613 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
NCT05807542 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
NCT02114658 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
NCT03957590 ·Status: COMPLETED ·Phase: PHASE3
-
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
NCT01142388 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT04732494 ·Status: COMPLETED ·Phase: PHASE2
-
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
NCT02530437 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
NCT06482086 ·Status: RECRUITING ·Phase: PHASE2
-
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
NCT05637268 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
NCT07039162 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
NCT02830594 ·Status: COMPLETED ·Phase: PHASE2
-
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
NCT05189730 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
NCT06709417 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542 ·Status: RECRUITING ·Phase: PHASE1
-
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
NCT00804830 ·Status: TERMINATED ·Phase: PHASE2
-
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
NCT06530316 ·Status: RECRUITING
-
A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
NCT07112833 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
NCT07067450 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer
NCT02762474 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2